Navigation Links
Mechanical Blood Clot 'Retrievers' May Aid Stroke Patients
Date:8/27/2012

MONDAY, Aug. 27 (HealthDay News) -- A new generation of "retriever" devices, designed to mechanically remove blood clots from arteries and restore blood flow in stroke patients, could improve treatment, studies suggest.

The most common treatment for stroke is taking a drug that dissolves the blood clot and reopens the blocked artery. The drug must be taken within three hours of the onset of stroke, however, and is not suitable for all patients. In addition, the drug often fails to dissolve large blood clots.

A different approach involves the use of a mechanical blood flow restoration device or "stent-triever" that is inserted through the groin and then guided to the site of the blood clot. The device retrieves and removes the blood clot and restores blood flow to the brain.

The U.S. Food and Drug Administration approved the first of these devices in 2004. The device, called the Merci retriever, has since been used in thousands of stroke patients worldwide.

In two studies, researchers evaluated two new mechanical clot retrievers and found that they have the potential to better restore blood flow and lead to improved patient outcomes.

One expert not connected to the studies explained how the new models, called Solitaire and Trevo, work.

"The new stent-trievers act as a temporary stent, not unlike a coronary stent and are opened temporarily within the clot within a [blocked] cerebral artery," said Dr. David Langer, a neurosurgeon at the Cushing Neuroscience Institute in Manhasset, N.Y. "This device restores flow by creating a channel within the vessel [opening] while also expanding into the clot itself, which hopefully is captured as the stent is pulled back."

One study was led by Dr. Jeffrey Saver of the UCLA Stroke Center. It compared the performance of the older Merci retriever to the Solitaire version. The randomized trial of 113 patients found that patient outcomes were much better among those treated with the Solitaire device.

Three months after treatment, 58 percent of patients treated with the Solitaire device had a good neurological outcome, compared with 33 percent of those treated with the Merci retriever. Patient death rates were 17 percent with Solitaire and 38 percent with Merci, the study found.

The second study, led by Raul Nogueira of the Marcus Stroke and Neuroscience Center in Atlanta, compared the Merci retriever against the Trevo device. The chance of having a fully independent life after a stroke was 40 percent for patients treated with Trevo and 22 percent for those treated with Merci, the study found.

Compared to Merci, both the Trevo and Solitaire devices were much better at restoring blood flow in affected arteries and have a similar or better safety profile.

The studies show "a significant benefit of these stent-trievers" over that of the Merci device, Langer said.

"These new devices may represent a major advance" in restoring blood flow to stroke patients, he said, "thus improving outcomes in treating these critically ill patients."

Both studies were funded by medical device makers: The Solitaire study was funded by Covidien, which is developing that device, while the Trevo study was funded by its maker, Stryker Neurovascular.

The studies were published online Aug. 26 in the journal The Lancet, and were also presented at this week's European Society of Cardiology Congress, in Munich, Germany.

Both Trevo and Solitaire have been approved for use in the Unite States and Europe. The findings, if confirmed by further studies, suggest that the devices could lead to significant improvements for stroke patients for whom clot-busting drug treatment is ineffective.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about stroke.

-- Robert Preidt

SOURCES: The Lancet, news release, Aug. 26, 2012; David Langer, M.D., neurosurgeon, Cushing Neuroscience Institute, Manhasset, N.Y.


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Mechanical tissue resuscitation technology shows promise
2. Mechanical Device Helps Kids Waiting for Heart Transplant
3. Infection Might Raise Blood Clot Risk for Older Adults: Study
4. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
5. Common Blood Pressure Drug Safe for Heart Failure: Study
6. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
7. High Blood Pressure May Be Especially Lethal for Blacks
8. Changes in gene expression may help explain high blood pressure in pregnancy
9. Researchers Develop Blood Test for Depression
10. Naturopathic care can improve blood sugar, mood in diabetes
11. Diabetes Groups Issue New Guidelines on Blood Sugar
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mechanical Blood Clot 'Retrievers' May Aid Stroke Patients
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take ... goals to better one’s life through God. “The Trials I Face to Receive God’s ... wrong places, found a love for writing. Green feels that expressing his feelings through ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. ... work and rolled up their sleeves to help with relief efforts. The team picked ... process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
Breaking Medicine Technology: